The exact molecular mechanism via which α-synuclein, the main protein involved in Parkinson’s pathogenesis, aggregates is yet to be understood completely. In a recently published study, a team of ...

Oligomeric forms of α-synuclein are increasingly recognized as the primary neurotoxic species in Parkinson’s disease (PD) and other synucleinopathies, contributing to synaptic dysfunction, ...

— Treatment of Parkinson's and Lewy body patient brain tissue with WTX-607 demonstrated highly specific binding to aggregates within neurons in patients' brain tissue and potent inhibition of ...

Figure 1: A fluorescent micrograph of a section of brain affected by Parkinson’s disease. Neuron nuclei are blue, while the protein alpha-synuclein is red. A team that included a RIKEN researcher has ...

Monitoring alpha-synuclein aggregation is of great interest for studying the pathogenesis of synucleinopathies, a group of neurodegenerative diseases that includes Parkinson's disease (PD), dementia ...

A team that includes a RIKEN researcher has refined a lab test for measuring protein aggregate levels in samples from patients with certain neurodegenerative diseases. This has the potential to ...

AC Immune SA has divulged compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of multiple system atrophy (MSA), Parkinson’s dementia, Lewy body ...

How long can someone bail water before the boat tips over? That depends on two opposing factors: the rush of water, and the fitness of the bailer. A similar push-and-pull may take place in ...

New York, USA, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight Alpha-synuclein ...

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic alpha-synuclein ...